Under the Paperwork Reduction Act of 1995, no persons are required to

Application Number		10579004		
Filing Date		2006-05-11		
First Named Inventor Dougl		as R. McPherson		
Art Unit		1731		
Examiner Name	Not Y	et Known		
Attorney Docket Number		A IE-2 209 1US		

				0.5	MILHIO				
Examiner Cite Initial* Cite No Patent Num		Patent Number	Kind Code ¹ Issue Date Name of cited		Name of Pa of cited Doc	Name of Patentee or Applicant Re		Pages,Columns,Lines where Relevant Passages or Relevan Tigures Appear	
	1	4909906		1990-03-20	Bartelmuss e	tal.			
	2	6221215		2001-04-24	Halmschlage	retal.			
If you wis	h to a	dd additional U.S. Pate	ent citatio	n information p	lease click the	Add button.		Add	
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date Name of Patent of cited Docume		tentee or Applicant ument	pe or Applicant nt Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1	20040074623		2004-04-22	Bartelmuss e	t al.			
If you wisl	h to a	dd additional U.S. Pub	lished Ap	plication citation	n information	please click the Ad	d button	Add	
				FOREIGN PA	TENT DOCU	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TG
	1	0454973	EP		1991-11-06	Simmons et al.			
	2	29822998	DE		1999-02-25	Voith Sulzer Papiertechnik Pate GmbH	ent		
			1		1	1			

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10579004
Filing Date		2006-05-11
First Named Inventor	Dougl	las R. McPherson
Art Unit		1731
Examiner Name	Not Y	et Known
Attorney Docket Number		AJE-2.209.1US

	3	0945545	EP		1999-09-29	Halmschlager et al.			
	4	1411166	EP		2005-04-21	Bartelmuss et al.			
If you wis	h to a	dd additional For	eign Patent Documer	t citation	information p	lease click the Add butto	n Add		
			NON-PATI	NT LIT	ERATURE DO	CUMENTS	Remove		
Examiner Initials*	kaminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city androf country where published.						Тв		
	1								
If you wis	h to a	dd additional non	-patent literature doc	ument ci	tation informat	ion please click the Add	button Add		
EXAMINER SIGNATURE									
Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

1 See Kind Code of USPTO Patent Documents at How (LISPTO_GOU) or MPEP 801.64. 2 Enter of thice that issued the document, by the Nov-letter of Kind Standard S13...) For Lispanese patent for comment, the middle contine the major comment process the sense in the Emperor may precede the sense in unwhere of the patent for which only the propriets emprisor as andicated on the document under WIPO Standard S11.68 if possible, 2 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10579004
Filing Date		2006-05-11
First Named Inventor	Dougl	las R. McPherson
Art Unit		1731
Examiner Name	Not Y	et Known
Attorney Docket Number		AJE-2.209.1US

CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1 98 to 1	make th	e anno	nnista e	alaction/	el·

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

To the agricults.						
	Signature	/Randolph J. Huis/	Date (YYYY-MM-DD)	2007-07-24		
	Name/Print	Randolph J. Huis	Registration Number	34626		

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.